drugset / Trial / NCT00732992

A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

NCT00732992

Phase 1 Completed 12 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule.

Timeline

Start
2008-08
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemetrexed Small molecule 500 mg/m2
Subject Sunitinib Small molecule 37.5 mg Oral
Subject Sunitinib Small molecule 50 mg Oral

Indications